Addex Therapeutics Ltd
SIX:ADXN
Addex Therapeutics Ltd
SIX:ADXN
Price:
0.0664 CHF
-2.64%
Market Closed
Updated:
Jun 1, 2024
Addex Therapeutics Ltd
Cash & Cash Equivalents
|
Addex Therapeutics Ltd
Cash & Cash Equivalents Peer Comparison
Comparables:
ACIU
CRSP
BSLN
IDIA
KURN
Competitive Cash & Cash Equivalents Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Addex Therapeutics Ltd
SIX:ADXN
|
Cash & Cash Equivalents
CHf4.8m
|
CAGR 3-Years
-37%
|
CAGR 5-Years
-35%
|
CAGR 10-Years
N/A
|
|
|
AC Immune SA
NASDAQ:ACIU
|
Cash & Cash Equivalents
CHf78.5m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
N/A
|
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Cash & Cash Equivalents
$707.4m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Cash & Cash Equivalents
CHf59.9m
|
CAGR 3-Years
0%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
-7%
|
|
|
Idorsia Ltd
SIX:IDIA
|
Cash & Cash Equivalents
CHf145.1m
|
CAGR 3-Years
1%
|
CAGR 5-Years
-29%
|
CAGR 10-Years
N/A
|
|
|
Kuros Biosciences AG
SIX:KURN
|
Cash & Cash Equivalents
CHf14.2m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
See Also
What is Addex Therapeutics Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
4.8m
CHF
4.8m
CHF
Based on the financial report for Dec 31, 2023, Addex Therapeutics Ltd's Cash & Cash Equivalents amounts to 4.8m CHF.
What is Addex Therapeutics Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 5Y
-35%
-35%
Over the last year, the Cash & Cash Equivalents growth was -54%. The average annual Cash & Cash Equivalents growth rates for Addex Therapeutics Ltd have been -37% over the past three years , -35% over the past five years .
You don't have any saved screeners yet
